Neuropace, Inc. (NPCE)
NASDAQ:NPCE
NPCE Stock Chart & Stats
$14.09
-$0.66(-5.31%)
At close: 4:00 PM EST
$14.09
-$0.66(-5.31%)
Day’s Range― - ―
52-Week Range$7.56 - $18.98
Previous CloseN/A
Volume21.31K
Average Volume (3M)223.15K
Market Cap
$480.09M
Enterprise Value$529.23M
Total Cash (Recent Filing)$61.06M
Total Debt (Recent Filing)$70.84M
Price to Earnings (P/E)―
Beta0.47
Next Earnings
May 07, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding33,666,946
10 Day Avg. Volume150,060
30 Day Avg. Volume223,145
Financial Highlights & Ratios
PEG Ratio0.81
Price to Book (P/B)26.55
Price to Sales (P/S)5.05
P/FCF Ratio-44.56
Enterprise Value/Market Cap1.10
Enterprise Value/Revenue5.29
Enterprise Value/Gross Profit6.85
Enterprise Value/Ebitda-38.36
Forecast
1Y Price Target
$19.33Price Target Upside37.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.62
Revenue Forecast (FY)$98.91M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthConsistent multi-year top-line expansion demonstrates durable commercial adoption of the RNS System across implanting centers. Persistent high growth expands installed base and aftermarket opportunity, supporting recurring device and component sales and improving scale economics over the next 2–6 months and beyond.
High Gross MarginsSustained, high product-level margins indicate strong unit economics for the RNS System, giving the company room to invest in sales and R&D while protecting profitability as revenue scales. Durable margin advantage can fund growth initiatives and absorb pricing/reimbursement pressures over time.
Regulatory & Product PipelineFDA acceptance for an IGE PMA supplement and submissions like Seizure ID plus cloud platform work represent structural product expansion and tech differentiation. Approval and AI-enabled features could materially enlarge addressable market and create durable clinical/competitive advantages over months to years.
Bears Say
Persistent Cash BurnOngoing negative operating and free cash flow, despite narrowing losses, means the business still consumes cash and depends on external funding or runway management. This structural cash burn constrains strategic flexibility and increases dilution/refinancing risk if growth slows or investments intensify.
Leverage & Equity VolatilityElevated and historically volatile leverage reduces financial resilience and raises refinancing and covenant risks. With material debt outstanding and equity swings, capital structure constraints could limit investment flexibility and heighten vulnerability to unforeseen operational or reimbursement headwinds.
Near-term Adjusted EBITDA LossGuided adjusted EBITDA loss driven by front-loaded commercial investments implies the company will need to sustain investment while remaining unprofitable in 2026. This delays durable profitability, maintains cash burn, and requires the business to execute conversion and coverage efforts to realize returns on the increased spend.
NeuroPace News
NPCE FAQ
What was Neuropace, Inc.’s price range in the past 12 months?
Neuropace, Inc. lowest stock price was $7.56 and its highest was $18.98 in the past 12 months.
What is Neuropace, Inc.’s market cap?
Neuropace, Inc.’s market cap is $480.09M.
When is Neuropace, Inc.’s upcoming earnings report date?
Neuropace, Inc.’s upcoming earnings report date is May 07, 2026 which is in 24 days.
How were Neuropace, Inc.’s earnings last quarter?
Neuropace, Inc. released its earnings results on Mar 03, 2026. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.156 by $0.076.
Is Neuropace, Inc. overvalued?
According to Wall Street analysts Neuropace, Inc.’s price is currently Undervalued.
Does Neuropace, Inc. pay dividends?
Neuropace, Inc. does not currently pay dividends.
What is Neuropace, Inc.’s EPS estimate?
Neuropace, Inc.’s EPS estimate is -0.22.
How many shares outstanding does Neuropace, Inc. have?
Neuropace, Inc. has 33,666,946 shares outstanding.
What happened to Neuropace, Inc.’s price movement after its last earnings report?
Neuropace, Inc. reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.156. Following the earnings report the stock price went up 0.868%.
Which hedge fund is a major shareholder of Neuropace, Inc.?
Currently, no hedge funds are holding shares in NPCE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NeuroPace Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.33 (37.19% Upside)
$19.33 (37.19% Upside)
Blogger Sentiment
Bullish
NPCE Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 583.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
34.02%
12-Months-Change
Fundamentals
Return on Equity
-105.67%
Trailing 12-Months
Asset Growth
104.90%
Trailing 12-Months
Company Description
Neuropace, Inc.
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.
NPCE Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial execution and material clinical and product progress: robust revenue growth (Q4 +24%, FY +25%), sustained RNS momentum, margin expansion, positive adjusted EBITDA and cash generation in Q4, and meaningful regulatory and AI product milestones (IGE PMA acceptance; Seizure ID submission). Offsetting items include an expected near-term adjusted EBITDA loss for 2026 (‑$9M to ‑$10M) due to front-loaded commercial investments and seasonality, the wind-down of the DIXI partnership, and the need for payer coverage work before any IGE approval translates into revenue. Overall, the positives around growth, margins, product/clinical milestones and disciplined operating leverage significantly outweigh the manageable near-term headwinds and investment-driven profitability pressure.View all NPCE earnings summariesNPCE Stock 12 Month Forecast
Average Price Target
$19.33
▲(37.19% Upside)
Technical Analysis
Delcath Systems
―
Senseonics Holdings
―
Tactile Systems Technology
―
RxSight
―
Ceribell, Inc.
―
Ownership Overview
Currently, No data available
---